DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Catapres (Clonidine Hydrochloride) - Indications and Dosage

 
 



INDICATIONS AND USAGE

Catapres-TTS transdermal therapeutic system is indicated in the treatment of hypertension. It may be employed alone or concomitantly with other antihypertensive agents.

DOSAGE AND ADMINISTRATION

Apply CATAPRES-TTS® (clonidine) transdermal therapeutic system once every 7 days to a hairless area of intact skin on the upper outer arm or chest. Each new application of CATAPRES-TTS transdermal therapeutic system should be on a different skin site from the previous location. If the system loosens during 7-day wearing, the adhesive cover should be applied directly over the system to ensure good adhesion. There have been rare reports of the need for patch changes prior to 7 days to maintain blood pressure control.

To initiate therapy, CATAPRES-TTS transdermal therapeutic system dosage should be titrated according to individual therapeutic requirements, starting with CATAPRES-TTS-1. If after one or two weeks the desired reduction in blood pressure is not achieved, increase the dosage by adding another CATAPRES-TTS-1 or changing to a larger system. An increase in dosage above two CATAPRES-TTS-3 is usually not associated with additional efficacy.

When substituting CATAPRES-TTS transdermal therapeutic system for oral clonidine or for other antihypertensive drugs, physicians should be aware that the antihypertensive effect of CATAPRES-TTS transdermal therapeutic system may not commence until 2-3 days after initial application. Therefore, gradual reduction of prior drug dosage is advised. Some or all previous antihypertensive treatment may have to be continued, particularly in patients with more severe forms of hypertension.

Renal Impairment

Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine following dialysis.

HOW SUPPLIED

CATAPRES-TTS-1, CATAPRES-TTS-2, and CATAPRES-TTS-3 are supplied as 4 pouched systems and 4 adhesive covers per carton. See chart below.

  Programmed Delivery
Clonidine in vivo
       
  Per Day Over 1 Week  
Clonidine
Content
 
Size
 
Code
Catapres-TTS®-1
(clonidine)
NDC 0597-0031-34
0.1 mg 2.5 mg 3.5 cm2 BI-31
Catapres-TTS®-2
(clonidine)
NDC 0597-0032-34
0.2 mg 5.0 mg 7.0 cm2 BI-32
Catapres-TTS®-3
(clonidine)
NDC 0597-0033-34
0.3 mg 7.5 mg 10.5 cm2  BI-33

STORAGE AND HANDLING

Store below 86°F (30°C).

Distributed by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT 06877 USA

Licensed from:
Boehringer Ingelheim International GmbH

Address medical inquiries to: (800) 542-6257 or (800) 459-9906 TTY.

Copyright 2012 Boehringer Ingelheim International GmbH
ALL RIGHTS RESERVED

Revised: May 2012
IT7000GF052012
4044415/09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017